SCHEMBL7230237

SCHEMBL7230237

Nc1cccc(-c2ncccc2[N+](=O)[O-])c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.47
PDE10A Q9Y233 1/20 0.47
PDE4D Q08499 3/20 0.47
POLB P06746 1/20 0.46
ALDH1A1 P00352 5/20 0.45
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
MEN1 O00255 2/20 0.42
AXL P30530 2/20 0.42
MKNK2 Q9HBH9 2/20 0.42
PSIP1 O75475 1/20 0.42
MKNK1 Q9BUB5 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
MAPT P10636 4/20 0.41
NPC1 O15118 1/20 0.40
PDE4A P27815 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27930436 0.83 TRPV1 (0.51) PDE10APOLBALDH1A1NCOA1NCOA3
SCHEMBL14053276 0.82 HSP90AA1 (0.49) PDE10APDE4DPOLBALDH1A1NCOA1
SCHEMBL8529578 0.82 PDE10A (0.47) MAP4K4PDE10APDE4DPOLBALDH1A1
SCHEMBL444703 0.80 ALDH1A1 (0.53) PDE10APDE4DPOLBALDH1A1NCOA1
SCHEMBL16097359 0.79 ERN1 (0.51) PDE10APDE4DALDH1A1TRPV1MAPT
SCHEMBL27866903 0.78 DYRK1A (0.56) PDE10APDE4DALDH1A1MEN1MAPT
SCHEMBL16119989 0.78 ALDH1A1 (0.51) MAP4K4PDE10APDE4DPOLBALDH1A1
SCHEMBL6235889 0.78 MAPT (0.50) PDE10APDE4DPOLBTRPV1CYP3A4
SCHEMBL30794281 0.78 PDE10A (0.46) PDE10APOLBALDH1A1NCOA1NCOA3
SCHEMBL7357488 0.78 MAPT (0.56) MAP4K4PDE10AALDH1A1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6521643-B1 Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 US disclosed
EP-1157022-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-28 EP disclosed
WO-2000049015-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-08-24 WO disclosed